The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
OBJECTIVE
In our pilot study, we used plasma samples as liquid biopsy to search for miRNA signatures in patients with acute myeloid leukemia (AML) at diagnosis and in remission achieved after standard chemotherapy before planned transplantation.


METHODS
We examined 10 plasma samples from healthy volunteers and 8 paired samples from patients with AML at diagnosis and in remission using TaqMan MicroRNA Arrays. The results were validated using single-target qPCR reactions run in triplicates.


RESULTS
We selected 6 miRNAs with expressions significantly sensitive to therapy: miR-199b-5p, miR-301b, miR-326, miR-361-5p, miR-625 and miR-655. All selected miRNAs were not or very weakly expressed in healthy individuals. They were abundant in plasma in patients at diagnosis but their levels decreased after chemotherapy.


CONCLUSIONS
We detected a therapy sensitive miRNA signature in plasma of patients with AML.
Department of Hematoonocology, Charles University Hospital in Pilsen, Alej Svobody 80, 304 60 Pilsen, Czech Republic.
Linda
L
Koutova
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
Monika
M
Sterbova
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
Eva
E
Pazourkova
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
Sarka
S
Pospisilova
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
Iveta
I
Svobodova
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
Ales
A
Horinek
Department of Hematoonocology, Charles University Hospital in Pilsen, Alej Svobody 80, 304 60 Pilsen, Czech Republic.
Daniel
D
Lysak
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic; Medical Faculty in Pilsen, Charles University in Prague, Husova 3, 306 05 Pilsen, Czech Republic. Electronic address: marie.korabecna@lf1.cuni.cz.
Marie
M
Korabecna
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D060830:Consolidation Chemotherapy; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D010865:Pilot Projects; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000097:blood* / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D012074:Remission Induction; D059467:Transcriptome
C550735:MIRN301A microRNA, human; C545322:MIRN326 microRNA, human; C575475:MIRN361 microRNA, human; C575476:MIRN625 microRNA, human; C585264:MIRN655 microRNA, human; D035683:MicroRNAs; D012334:RNA, Neoplasm; C531408:mirn199 microRNA, human; D003561:Cytarabine; D008942:Mitoxantrone; D015255:Idarubicin
Acute myeloid leukemia; Liquid biopsy; Plasma; Remission; Standard chemotherapy; miRNA signature